GSK to market Amgen's denosumab for osteoporosis
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to commercialise Amgen's investigational monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe and various other countries, including emerging markets. The antibody (Prolia is the proposed trade name) is also indicated for cancer, to which Amgen retains the rights in the major markets.